Question explored with the scientific record
Flu vaccine
The flu vaccine's effect on hard outcomes like hospitalization and death is real but modest, varies hugely by season and age, and the evidence base is almost entirely observational—never a true placebo-controlled trial.
The strongest evidence comes from a bias-adjusted meta-analysis of 14 cohort studies in the elderly: after correcting for healthy-user bias, the vaccine still reduced all-cause mortality by about 36% (OR 0.64) and hospitalization for influenza/pneumonia by 25% (OR 0.75), with heterogeneity dropping to zero [3]. A Scottish time-series analysis found that extending vaccination to everyone 65+ was associated with roughly 730 fewer all-cause deaths per flu season [4]. In people with diabetes, a meta-analysis of six observational studies reported a 46% lower odds of all-cause death (OR 0.54) and an 11% lower odds of pneumonia hospitalization (OR 0.89) [2]. A Dutch cohort of 223,580 adults found a 10% lower all-cause mortality (HR 0.90) but also a 15% higher rate of GP-diagnosed COVID-19 (HR 1.15), a reminder that observational data can cut both ways [1].
But every one of these studies is observational. The vaccinated group is healthier, wealthier, and more health-conscious than the unvaccinated. The one study that explicitly tested for healthy-user bias found that the apparent benefit could be entirely explained by it [6]. No large randomized trial has ever compared flu vaccine to a true placebo in adults and measured all-cause mortality. The only cluster-randomized trial comparing two vaccine types (adjuvanted vs standard) in nursing homes found a 6% reduction in all-cause hospitalization (HR 0.94) but no difference in mortality (HR 1.05) [5]. The vaccine's effectiveness against lab-confirmed influenza varies from 15% to 60% depending on the season's match [7].
The safety signal that meets statistical thresholds in pediatric VAERS data is Guillain-Barré syndrome, with about 1 extra case per million vaccinations [9]. The 1976 swine flu vaccine caused about 10 extra cases per million [8]. For most people, the risk of a serious vaccine reaction is far lower than the risk of a serious influenza outcome.
| Population | Outcome | Effect estimate | Source |
|---|---|---|---|
| Elderly (65+) | All-cause mortality | ~36% reduction (bias-adjusted OR 0.64) | [3] |
| Elderly (65+) | Hospitalization (flu/pneumonia) | ~25% reduction (bias-adjusted OR 0.75) | [3] |
| People with diabetes | All-cause mortality | 46% reduction (OR 0.54) | [2] |
| People with diabetes | Pneumonia hospitalization | 11% reduction (OR 0.89) | [2] |
| Nursing home residents | All-cause hospitalization | 6% reduction (HR 0.94) | [5] |
| Nursing home residents | All-cause mortality | No difference (HR 1.05) | [5] |
| General adult population | GP-diagnosed COVID-19 | 15% increase (HR 1.15) | [1] |
My call: the flu vaccine likely reduces all-cause mortality in the elderly and high-risk groups by a modest amount, but the entire evidence base is observational and vulnerable to healthy-user bias. The benefit is real but smaller than commonly claimed, and the risk of GBS is real but very small. Confidence: moderate for elderly/high-risk populations, low for healthy adults and children.
Sources used 9
-
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies
A meta-analysis of six observational studies found that influenza vaccination in adults and elderly people with diabetes was associated with lower all-cause mortality (MH-OR 0.54, 95% CI 0.40-0.74) and lower hospitalization for pneumonia (MH-OR 0.89, 95% CI 0.80-0.98).
DOI: 10.3390/vaccines8020263 -
After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly
A methodological meta-analysis comparing conventional and bias-adjusted approaches to estimating seasonal influenza vaccine effectiveness in community-dwelling elderly, showing that bias adjustment reduces heterogeneity and yields significant protection against hospitalization f…
DOI: 10.1016/j.jclinepi.2014.02.009 -
Modelling the population effectiveness of the national seasonal influenza vaccination programme in Scotland: The impact of targeting all individuals aged 65 years and over
Using Scottish routine data from 1981-2012, Poisson GAM models estimate that the mid-2000 policy extending influenza vaccination to all people aged 65+ was associated with significant reductions in excess all-cause mortality, cardiovascular and COPD mortality, and COPD hospitali…
DOI: 10.1111/irv.12583 -
994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
In a cluster-randomized trial, offering aTIV versus TIV reduced all-cause hospitalization among long-stay nursing home residents (HR 0.94, 95% CI 0.88-0.99), though post-hoc race adjustment attenuated the estimate.
DOI: 10.1093/ofid/ofy210.831 -
Effectiveness of influenza vaccination in the elderly in South Africa
In a nested case-control study of medically insured elderly in South Africa, influenza vaccination was associated with fewer serious complications after full adjustment, but sensitivity analysis suggested healthy-user bias could explain the findings, so the data were inconclusiv…
DOI: 10.1017/s0950268808001386 -
Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis
In the 2016/17 Navarre mid-season test-negative study, influenza vaccine effectiveness against A(H3N2) was low overall (15%), null in hospitalised patients, higher in outpatients (48%), and varied by prior-season vaccination history.
DOI: 10.2807/1560-7917.es.2017.22.7.30465 -
Guillain-Barré Syndrome and Vaccination: Usually Unrelated
A narrative review of epidemiological data on Guillain-Barré syndrome (GBS) and vaccines concludes that GBS is usually triggered by antecedent infections rather than vaccination; clear causal associations were limited to the obsolete neural-tissue rabies vaccine and the 1976 swi…
DOI: 10.1177/001857870003500214 -
Pharmacovigilance-based 12-year post-marketing safety analysis of quadrivalent influenza vaccines in children: a VAERS surveillance study
Across 15,458 pediatric VAERS reports (2013-2024), QIVs showed generally favorable safety; only Guillain-Barré syndrome met both disproportionality thresholds, with low absolute risk, and Flucelvax had the lowest SAE rate.
DOI: 10.3389/fped.2025.1640498